WARRINGTON, Pa., March 16, 2016 /PRNewswire/ -- Discovery
Laboratories, Inc. (Nasdaq: DSCO), a biotechnology company
focused on developing aerosolized KL4 surfactant therapies for
respiratory diseases, will report fourth quarter 2015
financial results and provide business updates on Thursday, March 24, 2016 before the open of the
U.S. financial markets.
The Company will also host a live teleconference and webcast,
including a slide presentation, at 8:00 a.m. EDT on the same
day to discuss the 2015 fourth quarter financial results along with
providing other business updates. The live webcast and archive of
the conference call can be accessed at
http://discoverylabs.investorroom.com/events.
For "listen-only" participants and those who wish to take part
in the question and answer portion of the call, dial (888) 346-0767
(domestic) or (412) 902-4251 (international). After placing the
call, request to be joined into the Discovery Labs conference
call. A replay of the conference call will be accessible one
hour after completion through March 31,
2016 by dialing (877) 344-7529 (domestic) or (412) 317-0088
(international) and referencing conference ID number 10082877.
About Discovery Labs
Discovery Laboratories, Inc. is a biotechnology company focused
on developing aerosolized KL4 surfactant therapies for respiratory
diseases. Surfactants are produced naturally in the lung and
are essential for normal respiratory function and survival.
If surfactant deficiency or degradation occurs, the air sacs in the
lungs can collapse, resulting in severe respiratory diseases and
disorders. Discovery Labs' technology platform includes a
novel synthetic peptide-containing (KL4) surfactant, that is
structurally similar to pulmonary surfactant, and proprietary drug
delivery technologies being developed to enable efficient delivery
of aerosolized KL4 surfactant. Discovery Labs believes that
its proprietary technology platform makes it possible, for the
first time, to develop a significant pipeline of aerosolized
surfactant products to address a variety of respiratory diseases
for which there frequently are few or no approved therapies.
For more information, please visit the Company's website at
www.Discoverylabs.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/discovery-labs-to-report-fourth-quarter-2015-financial-results-and-host-conference-call-on-thursday-march-24-2016-300237414.html
SOURCE Discovery Laboratories, Inc.